Previous studies have shown that enrichment of CXCL13+T cells, which express high levels of PDCD1 and CTLA4, are associated with enhanced sensitivity to immunotherapy targeting PD1 or CTLA4 in CRC patients [26]. This evidence concerns the gene CXCL13 and colorectal carcinoma.